Elo Mutual Pension Insurance Co Lowers Stock Position in Exact Sciences Co. (NASDAQ:EXAS)

Elo Mutual Pension Insurance Co decreased its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 22.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,710 shares of the medical research company’s stock after selling 3,681 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Exact Sciences were worth $714,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of EXAS. Groupama Asset Managment acquired a new position in Exact Sciences during the third quarter valued at approximately $821,000. ArrowMark Colorado Holdings LLC purchased a new stake in Exact Sciences during the 3rd quarter worth $28,608,000. Iron Triangle Partners LP acquired a new stake in Exact Sciences in the 3rd quarter valued at $27,239,000. Erste Asset Management GmbH purchased a new position in Exact Sciences in the third quarter valued at about $26,546,000. Finally, Bellevue Group AG lifted its stake in shares of Exact Sciences by 25.1% during the third quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company’s stock worth $98,738,000 after purchasing an additional 290,585 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Benchmark reiterated a “buy” rating and set a $65.00 target price on shares of Exact Sciences in a report on Monday, January 13th. William Blair reissued an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 20th. Guggenheim set a $60.00 price target on shares of Exact Sciences and gave the company a “buy” rating in a report on Friday. Barclays cut their price objective on shares of Exact Sciences from $70.00 to $65.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. Finally, Scotiabank raised their target price on Exact Sciences from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research note on Monday, February 24th. Two investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $70.26.

Exact Sciences Stock Down 3.0 %

Exact Sciences stock opened at $43.66 on Monday. The firm has a market capitalization of $8.11 billion, a P/E ratio of -7.84 and a beta of 1.25. The company has a 50-day simple moving average of $49.71 and a 200-day simple moving average of $57.75. Exact Sciences Co. has a one year low of $40.62 and a one year high of $79.62. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.23. The company had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. As a group, equities analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.